

# Alexandre R Zlotta

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8289580/alexandre-r-zlotta-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

199  
papers

7,536  
citations

46  
h-index

81  
g-index

223  
ext. papers

9,161  
ext. citations

5.3  
avg, IF

5.58  
L-index

#	Paper	IF	Citations
199	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.. <i>European Radiology</i> , <b>2022</b> , 1	8	0
198	Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. <i>European Urology Focus</i> , <b>2021</b> , 7, 1044-1051	5.1	3
197	Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach. <i>European Urology Focus</i> , <b>2021</b> , 7, 582-588	5.1	4
196	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259272	3.7	0
195	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. <i>Nature Communications</i> , <b>2021</b> , 12, 6248	17.4	3
194	MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. <i>Radiology</i> , <b>2021</b> , 298, 695-703	20.5	9
193	Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, E424-E460	1.2	1
192	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , <b>2021</b> , 79, 480-488	10.2	51
191	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , <b>2021</b> , 4, 182-191	6.7	15
190	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 835.e1-835.e7	2.8	0
189	100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 611-622	5.5	19
188	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5775-5782	4.8	2
187	Novel use of an old compound? Urologist-led Bacille Calmette-Guérin vaccine trials in the prevention of coronavirus disease 2019. <i>BJU International</i> , <b>2021</b> , 127, 35-36	5.6	
186	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. <i>Prostate</i> , <b>2021</b> , 81, 286-294	4.2	0
185	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , <b>2021</b> , 300, 369-379	20.5	5
184	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , <b>2021</b> , 80, 374-382	10.2	7
183	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> ,	2.8	2

182	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, 404-410	1.2	1
181	Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-based, Diagnostic Study. <i>European Urology</i> , <b>2020</b> , 78, 290-291	10.2	2
180	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 603.e1-603.e7	2.8	7
179	Are there differences among bacillus Calmette-Guérin (BCG) strains regarding their clinical efficacy in the treatment of non-muscleinvasive bladder cancer? The jury is still out but the answer is likely no. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E54-E56	1.2	
178	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (18F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5553-5553	2.2	1
177	Trimodal therapy in muscle invasive bladder cancer management. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , <b>2020</b> , 72, 650-662	4.4	3
176	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. <i>Journal of Urology</i> , <b>2020</b> , 204, 476-482	2.5	2
175	A Prospective Randomized Controlled Trial of Irrigation "Bag Squeeze" to Manage Pain for Patients Undergoing Flexible Cystoscopy. <i>Journal of Urology</i> , <b>2020</b> , 204, 1012-1018	2.5	8
174	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 440-448	2.8	14
173	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. <i>BJU International</i> , <b>2020</b> , 125, 525-530	5.6	16
172	Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening: Against increasing PSA threshold to 10 ng/ml. <i>European Urology</i> , <b>2020</b> , 78, 927-929	10.2	2
171	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?. <i>European Urology</i> , <b>2020</b> , 78, 682-687	10.2	20
170	Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 850.e9-850.e15	2.8	9
169	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. <i>European Urology Open Science</i> , <b>2020</b> , 22, 61-73	0.9	3
168	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , <b>2020</b> , 77, 420-433	10.2	309
167	Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 30-39	5.1	3
166	An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 39.e1-39.e9	2.8	6
165	Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?. <i>PLoS ONE</i> , <b>2019</b> , 14, e0216255	3.7	15

164	The use of intravesical BCG in urothelial carcinoma of the bladder. <i>Ecancermedicalscience</i> , <b>2019</b> , 13, 905	2.7	31
163	Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression. <i>Clinical Epigenetics</i> , <b>2019</b> , 11, 54	7.7	8
162	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 61-66	4	3
161	Lynch Syndrome in Urologic Malignancies - What Does the Urologist Need to Know?. <i>Urology</i> , <b>2019</b> , 134, 24-31	1.6	4
160	Reply by Authors. <i>Journal of Urology</i> , <b>2019</b> , 202, 325	2.5	
159	Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population Based Study. <i>Journal of Urology</i> , <b>2019</b> , 202, 319-325	2.5	1
158	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. <i>Canadian Urological Association Journal</i> , <b>2019</b> , E292-E299	1.2	
157	Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1676-1684	7.5	28
156	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 38-45	3.3	18
155	Comprehensive Imaging and Surgical Review of Urinary Diversions: What the Radiologist Needs to Know. <i>Current Problems in Diagnostic Radiology</i> , <b>2019</b> , 48, 161-171	1.6	2
154	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2019</b> , 230-238	1.2	21
153	A novel predictor of clinical progression in patients on active surveillance for prostate cancer. <i>Canadian Urological Association Journal</i> , <b>2019</b> , 13, 250-255	1.2	2
152	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 240.e13-240.e20	2.8	6
151	The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer. <i>BJU International</i> , <b>2018</b> , 122, 978-985	5.6	16
150	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. <i>Journal of Urology</i> , <b>2018</b> , 199, 1182-1187	2.5	20
149	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial. <i>European Radiology</i> , <b>2018</b> , 28, 4281-4287	8	19
148	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , <b>2018</b> , 200, 1056-1061	2.5	1
147	Editorial Comment. <i>Journal of Urology</i> , <b>2018</b> , 199, 967	2.5	

146	Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, 203-210	1.2	6
145	Statin use and time to progression in men on active surveillance for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2018</b> , 21, 509-515	6.2	5
144	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. <i>European Urology</i> , <b>2018</b> , 73, 543-557	15.7	66
143	Molecular Characterization of Bladder Cancer. <i>Current Urology Reports</i> , <b>2018</b> , 19, 107	2.9	7
142	Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, E210-E218	1.2	5
141	A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. <i>Nature Communications</i> , <b>2018</b> , 9, 3510	17.4	37
140	Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 361.e7-361.e13	2.8	14
139	Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer. <i>Translational Oncology</i> , <b>2017</b> , 10, 168-177	4.9	22
138	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	12
137	Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. <i>BJU International</i> , <b>2017</b> , 120, 76-82	5.6	11
136	What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, 118-122	1.2	2
135	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, 41-46	1.2	7
134	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2299-2305	2.2	153
133	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 604.e17-604.e24	2.8	2
132	A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1974-1980	12.9	25
131	Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. <i>Journal of Urology</i> , <b>2017</b> , 197, 335-341	2.5	30
130	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. <i>Journal of Urology</i> , <b>2017</b> , 197, 75-83	2.5	32
129	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. <i>European Urology</i> , <b>2016</b> , 69, 300-10	10.2	285

128	Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis. <i>Clinical Epigenetics</i> , <b>2016</b> , 8, 32	7.7	16
127	Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 207-12	8.7	38
126	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. <i>Urology</i> , <b>2016</b> , 93, 77-85	1.6	23
125	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. <i>Journal of Urology</i> , <b>2016</b> , 195, 307-12	2.5	9
124	A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , <b>2016</b> , 7, 57726-57736	3.3	40
123	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, 25-30	1.2	15
122	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, E424-E427	1.2	4
121	What's new in bladder cancer research?. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, S134-S135	1.2	
120	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , <b>2016</b> , 2, 263-272	1	6
119	Treatment of bladder cancer in the elderly. <i>Investigative and Clinical Urology</i> , <b>2016</b> , 57 Suppl 1, S26-35	1.9	19
118	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. <i>Journal of Urology</i> , <b>2016</b> , 196, 1645-1650	2.5	14
117	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 386.e7-13	2.8	28
116	Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. <i>Journal of Urology</i> , <b>2015</b> , 193, 1519-24	2.5	75
115	Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. <i>European Urology</i> , <b>2015</b> , 68, 1007-13	10.2	178
114	Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. <i>Modern Pathology</i> , <b>2015</b> , 28, 695-705	9.8	26
113	Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. <i>European Urology</i> , <b>2015</b> , 67, 64-70	10.2	66
112	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. <i>Prostate</i> , <b>2015</b> , 75, 1277-84	4.2	40
111	Health-related quality of life in robotic versus open radical prostatectomy. <i>Canadian Urological Association Journal</i> , <b>2015</b> , 9, 179-87	1.2	8

110	CUA guidelines on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2015</b> , 9, E690-704	1.2	53
109	The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. <i>Urology</i> , <b>2014</b> , 84, 1073-80	1.6	1
108	Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. <i>European Urology</i> , <b>2014</b> , 66, 841-8	10.2	46
107	Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer. <i>European Urology</i> , <b>2014</b> , 66, 982-6	10.2	27
106	Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. <i>European Urology</i> , <b>2014</b> , 66, 619-22	10.2	43
105	FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2014</b> , 465, 207-13	5.1	17
104	Lean methodology improves efficiency in outpatient academic uro-oncology clinics. <i>Urology</i> , <b>2014</b> , 83, 992-7	1.6	29
103	The importance of surgeon characteristics on impacting oncologic outcomes for patients undergoing radical cystectomy. <i>Journal of Urology</i> , <b>2014</b> , 192, 714-9	2.5	19
102	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, 309-16	1.2	12
101	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, 47-52	1.2	10
100	Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort. <i>Urology</i> , <b>2014</b> , 83, 81-7	1.6	20
99	Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression. <i>Journal of Urology</i> , <b>2014</b> , 192, 1088-93	2.5	6
98	A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression. <i>European Urology</i> , <b>2014</b> , 66, 406-13	10.2	27
97	Urothelial Bladder Cancer Urinary Biomarkers. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , <b>2014</b> , 25, 99-114	2.4	4
96	Prevalence of prostate cancer across the globe: what can autopsy studies teach us about this peculiar disease?. <i>Archivos Espanoles De Urologia</i> , <b>2014</b> , 67, 400-8	0.4	3
95	Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. <i>European Urology</i> , <b>2013</b> , 63, 379-85	10.2	63
94	Demographic analysis of randomized controlled trials in bladder cancer. <i>BJU International</i> , <b>2013</b> , 111, 419-26	5.6	4
93	Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols. <i>World Journal of Urology</i> , <b>2013</b> , 31, 161-7	4	20

92	Words of wisdom: Re: Genome sequencing identifies a basis for everolimus sensitivity. <i>European Urology</i> , <b>2013</b> , 64, 516	10.2	6
91	Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. <i>European Urology</i> , <b>2013</b> , 64, 421-30	10.2	101
90	Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. <i>European Urology</i> , <b>2013</b> , 63, 1049-58	10.2	47
89	Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. <i>Canadian Urological Association Journal</i> , <b>2013</b> , 7, 312-8	1.2	17
88	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. <i>BJU International</i> , <b>2013</b> , 112, 623-37	5.6	22
87	Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1050-8	9.7	164
86	Oncologic outcomes following radical prostatectomy in the active surveillance era. <i>Canadian Urological Association Journal</i> , <b>2013</b> , 7, E475-80	1.2	13
85	A new and highly prognostic system to discern T1 bladder cancer substage. <i>European Urology</i> , <b>2012</b> , 61, 378-84	10.2	117
84	Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. <i>BJU International</i> , <b>2012</b> , 110, 804-11	5.6	73
83	Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. <i>BJU International</i> , <b>2012</b> , 110, 1169-76	5.6	48
82	Does patient age affect survival after radical cystectomy?. <i>BJU International</i> , <b>2012</b> , 110, E486-93	5.6	24
81	Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. <i>European Urology</i> , <b>2012</b> , 62, 1088-96	10.2	57
80	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. <i>Epigenetics</i> , <b>2012</b> , 7, 1037-45	5.7	38
79	Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. <i>BJU International</i> , <b>2012</b> , 109, 70-6	5.6	20
78	Canadian Consensus Conference: The FDA decision on the use of 5ARIs. <i>Canadian Urological Association Journal</i> , <b>2012</b> , 6, 83-8	1.2	5
77	What is the future of virtual cystoscopy in urology?. <i>Canadian Urological Association Journal</i> , <b>2011</b> , 5, 38-9	1.2	6
76	Chemoprevention of prostate cancer: is there evidence from clinical trials?. <i>Clinical Investigation</i> , <b>2011</b> , 1, 1257-1268		1
75	Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. <i>BJU International</i> , <b>2011</b> , 107, 540-6	5.6	27



74	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. <i>BJU International</i> , <b>2011</b> , 108, 24-30	5.6	90
73	Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. <i>BJU International</i> , <b>2011</b> , 108, E237-44	5.6	51
72	Impact of 5 $\alpha$ -reductase inhibitors on men followed by active surveillance for prostate cancer. <i>European Urology</i> , <b>2011</b> , 59, 509-14	10.2	46
71	Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. <i>European Urology</i> , <b>2011</b> , 59, 1026-31	10.2	39
70	Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. <i>European Urology</i> , <b>2011</b> , 60, 484-92	10.2	142
69	Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist's practice patterns. <i>International Urology and Nephrology</i> , <b>2011</b> , 43, 31-7	2.3	3
68	Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records. <i>Journal of the American Medical Association</i> ; <i>JAMA</i> , <b>2011</b> , 306, 835-41	8.6	6
67	Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Gu $\acute{e}$ rin. <i>Urology Annals</i> , <b>2011</b> , 3, 119-26	1	20
66	'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. <i>BJU International</i> , <b>2010</b> , 105, 1231-6	5.6	155
65	Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression?. <i>Urology Annals</i> , <b>2010</b> , 2, 58-62	1	8
64	Optimal timing of radical cystectomy in T1 high-grade bladder cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 1891-902	3.5	6
63	Clinical significance of the positive surgical margin based upon location, grade, and stage. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2010</b> , 28, 197-204	2.8	28
62	Staging and Staging Errors in Bladder Cancer. <i>European Urology Supplements</i> , <b>2010</b> , 9, 2-9	0.9	45
61	Pathological stage review is indicated in primary pT1 bladder cancer. <i>BJU International</i> , <b>2010</b> , 106, 206-11	5.6	42
60	An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. <i>European Urology</i> , <b>2010</b> , 57, 60-70	10.2	141
59	The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. <i>European Urology</i> , <b>2010</b> , 57, 1052-7	10.2	57
58	A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution?. <i>European Urology</i> , <b>2010</b> , 58, 374-83	10.2	40
57	Word of wisdom. Re: a sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. <i>European Urology</i> , <b>2010</b> , 58, 943-4	10.2	

56	The management of BCG failure in non-muscle-invasive bladder cancer: an update. <i>Canadian Urological Association Journal</i> , <b>2009</b> , 3, S199-205	1.2	61
55	Lymphadenectomy in the surgical management of penile cancer. <i>European Urology</i> , <b>2009</b> , 55, 1075-88	10.2	149
54	Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. <i>European Urology</i> , <b>2009</b> , 56, 430-42	10.2	466
53	Prostate cancer: a serious disease suitable for prevention. <i>BJU International</i> , <b>2009</b> , 103, 864-70	5.6	29
52	The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma. <i>BJU International</i> , <b>2009</b> , 104, 1641-5	5.6	2
51	Focal Therapy Will Be the Future Treatment Modality: The Motion $\square$ <i>European Urology Supplements</i> , <b>2009</b> , 8, 433-438	0.9	3
50	Weighing the data on diet and prostate cancer. <i>Canadian Urological Association Journal</i> , <b>2008</b> , 2, 516-7	1.2	1
49	Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. <i>American Journal of Kidney Diseases</i> , <b>2008</b> , 51, 471-7	7.4	82
48	The REDUCE trial: chemoprevention in prostate cancer using a dual 5 $\alpha$ -reductase inhibitor, dutasteride. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 1073-9	3.5	27
47	Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7385-90	12.9	43
46	Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. <i>Therapeutics and Clinical Risk Management</i> , <b>2008</b> , 4, 11-8	2.9	3
45	Prostate cancer prevention: past, present, and future. <i>Cancer</i> , <b>2007</b> , 110, 1889-99	6.4	51
44	Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. <i>Modern Pathology</i> , <b>2007</b> , 20, 445-59	9.8	112
43	The medical management of prostate cancer: a multidisciplinary team approach. <i>BJU International</i> , <b>2007</b> , 99, 22-7	5.6	26
42	Laparoscopic partial nephrectomy with "on-demand" clamping reduces warm ischemia time. <i>European Urology</i> , <b>2007</b> , 52, 804-09	10.2	71
41	Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. <i>European Urology</i> , <b>2007</b> , 52, 1309-22	10.2	259
40	Auto-Antibody Signatures in Prostate Cancer. <i>European Urology</i> , <b>2006</b> , 49, 410-411	10.2	
39	Words of wisdom. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. <i>European Urology</i> , <b>2006</b> , 49, 757-8	10.2	2

38	Immediate versus deferred androgen-deprivation therapy for prostate cancer: the jury is still out. <i>Nature Reviews Urology</i> , <b>2006</b> , 3, 474-5		1
37	Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 1685-99	4	4
36	Hormone Therapy: Improving Therapy Decisions and Monitoring. <i>European Urology Supplements</i> , <b>2006</b> , 5, 369-376	0.9	7
35	How do I treat and follow my TUNA patients. <i>World Journal of Urology</i> , <b>2006</b> , 24, 397-404	4	8
34	Quality of Life after Radical Prostatectomy: How to Preserve Potency?. <i>European Urology Supplements</i> , <b>2005</b> , 4, 2-7	0.9	2
33	The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 273-85	3.5	4
32	Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection. <i>Urology</i> , <b>2005</b> , 65, 533-7	1.6	23
31	Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. <i>BJU International</i> , <b>2005</b> , 95, 285-90	5.6	5
30	Modified specimen retrieval facilitates urethro-vesical anastomosis in laparoscopic radical prostatectomy. <i>BJU International</i> , <b>2005</b> , 95, 447-9	5.6	0
29	Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. <i>European Urology</i> , <b>2005</b> , 48, 269-76	10.2	52
28	Prognosis of T1G3 Tumors: Clinical Factors. <i>European Urology Supplements</i> , <b>2004</b> , 3, 73-78	0.9	5
27	Is seminal vesicle ablation mandatory for all patients undergoing radical prostatectomy? A multivariate analysis on 1283 patients. <i>European Urology</i> , <b>2004</b> , 46, 42-9	10.2	38
26	Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. <i>World Journal of Urology</i> , <b>2003</b> , 20, 360-6	4	127
25	PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. <i>European Urology</i> , <b>2003</b> , 43, 12-27	10.2	63
24	Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. <i>European Urology</i> , <b>2003</b> , 44, 89-93	10.2	79
23	An artificial neural network to predict the outcome of repeat prostate biopsies. <i>Urology</i> , <b>2003</b> , 62, 456-60	6	58
22	The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 1240-7	12.9	9
21	Computerised assessment of maximum urinary flow: an efficient, consistent and valid approach. <i>European Urology</i> , <b>2002</b> , 41, 206-13; discussion 213	10.2	1

20	Repeat prostate biopsy: who, how and when?. a review. <i>European Urology</i> , <b>2002</b> , 42, 93-103	10.2	85
19	Comparison of laparoscopic radical prostatectomy techniques. <i>Current Urology Reports</i> , <b>2002</b> , 3, 148-51	2.9	16
18	Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data. <i>Current Opinion in Urology</i> , <b>2002</b> , 12, 7-14	2.8	20
17	Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. <i>Urology</i> , <b>2002</b> , 60, 4-9	1.6	193
16	Can survival be prolonged for patients with hormone-resistant prostate cancer?. <i>Lancet, The</i> , <b>2001</b> , 357, 326-7	40	12
15	4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. <i>European Urology</i> , <b>2000</b> , 38, 706-13	10.2	179
14	What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?. <i>International Journal of Cancer</i> , <b>2000</b> , 87, 844-52	7.5	56
13	Neoadjuvant and adjuvant hormone therapy for prostate cancer. <i>World Journal of Urology</i> , <b>2000</b> , 18, 179-82	4	7
12	Biological markers in superficial bladder tumors and their prognostic significance. <i>Urologic Clinics of North America</i> , <b>2000</b> , 27, 179-89, xi-xii	2.9	28
11	Laparoscopic partial bladder resection for bladder endometriosis. <i>Gynaecological Endoscopy</i> , <b>1999</b> , 8, 11-15		0
10	PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. <i>Urology</i> , <b>1999</b> , 54, 517-22	1.6	127
9	Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?. <i>Urology</i> , <b>1999</b> , 54, 846-52	1.6	62
8	Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. <i>Journal of Endourology</i> , <b>1997</b> , 11, 251-8	2.7	314
7	Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. <i>Urology</i> , <b>1997</b> , 50, 986-92; discussion 992-3	1.6	75
6	Is one single prostate biopsy helpful for choosing a medical treatment of benign prostatic hyperplasia? A quantitative computerized morphometric study. <i>Urology</i> , <b>1996</b> , 47, 329-34	1.6	21
5	Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. <i>Urology</i> , <b>1995</b> , 45, 28-33	1.6	98
4	Transurethral needle ablation of the prostate. <i>Current Opinion in Urology</i> , <b>1995</b> , 5, 35-38	2.8	14
3	Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. <i>European Urology</i> , <b>1993</b> , 24, 415-23	10.2	102

- 2 Transurethral needle ablation (TUNA): thermal gradient mapping and comparison of lesion size in a tissue model and in patients with benign prostatic hyperplasia. *European Urology*, **1993**, 24, 411-4 10.2 46
- 1 Utility of urine biomarkers26-38